Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

9 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

Efficacy and Safety of ADVAIR DISKUS Plus Spiriva HandiHaler Versus Spiriva HandiHaler in COPD NCT00784550 - Subject-Completed Rating Scales & Questionnaires

- 01/12/2020 - 1 Formulário, 2 Grupos de itens, 9 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, Subject-completed Rating Scales & Questionnaires
Study ID: 111114 Clinical Study ID: 111114 Study Title: A Randomized, Double-Blind, Parallel-Group, 24-Week Study to Evaluate the Efficacy and Safety of ADVAIR™ DISKUS™ (Fluticasone Propionate/Salmeterol Combination Product 250/50mcg Inhalation Powder) BID Plus Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder 18mcg) QD Versus Spiriva QD Plus Placebo DISKUS BID in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00784550 https://clinicaltrials.gov/ct2/show/NCT00784550 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: N/A Trade Name: Tiotropium Bromide, Fluticasone Propionate/Salmeterol Study Indication: Pulmonary Disease, Chronic Obstructive The purpose of the study is to determine the efficacy and safety of the combination of ADVAIR DISKUS® 250/50mcg (FLUTICASONE PROPIONATE/SALMETEROL COMBINATION PRODUCT) plus SPIRIVA® HANDIHALER® inhaler 18mcg (TIOTROPIUM) compared to SPIRIVA® HANDIHALER® inhaler 18mcg (TIOTROPIUM) in patients with COPD. There are a total of 6 visits: Screening (Visit 1), Randomization (Visit 2), and after 4 (Visit 3), 8 (Visit 4), 16 (Visit 5) and 24 (Visit 6) weeks of treatment. This form (Subject-Completed Rating Scales & Questionnaires) is to be filled out at Visit 2, 4 and 6 and/or in case of Early Withdrawal.

Humangenetik Darmkrebs MS University Hospital Muenster (UKM)

- 04/10/2016 - 1 Formulário, 1 Grupo de itens, 7 Elementos de dados, 1 Idioma
Grupo de itens: Questionnaire Hereditary Colorectal Carcinoma
Hospital Routine Documentation Form at the University Hospital Muenster. Original Form name: Fragebogen zur Ermittlung des Risikos für familliären Darmkrebs. (c) Humangenetik, Universitätsklinikum Bonn, Institut für Humangenetik, Prof. Dr. med. Markus Nöthen

Patient questionnaire PETAL Study NCT00554164 - Patient questionnaire

- 24/10/2016 - 1 Formulário, 1 Grupo de itens, 32 Elementos de dados, 2 Idiomas
Grupo de itens: Patient questionnaire
Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (PETAL-Studie) Universitätsklinikum Essen (UK Essen) EudraCT-Nummer: 2006-001641-33 NCT00554164

VISUAL FUNCTIONING QUESTIONNAIRE - 25 (DAY 0) CRFs Roche FVF4170G Macular Edema NCT-Nummer: NCT00473382

- 27/07/2017 - 1 Formulário, 2 Grupos de itens, 39 Elementos de dados, 2 Idiomas
Grupos de itens: Patient administration, VISUAL FUNCTIONING QUESTIONNAIRE - 25 (DAY 0)
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

VISUAL FUNCTIONING QUESTIONNAIRE - 25 (DAY 0) CRFs Roche FVF4168G Macular Edema NCT00473330

- 27/07/2017 - 1 Formulário, 2 Grupos de itens, 39 Elementos de dados, 2 Idiomas
Grupos de itens: Patient administration, VISUAL FUNCTIONING QUESTIONNAIRE - 25 (DAY 0)
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

RetDQoL (DAY 0) CRFs Roche FVF4170G Macular Edema NCT00473382

- 09/06/2017 - 1 Formulário, 2 Grupos de itens, 3 Elementos de dados, 1 Idioma
Grupos de itens: Patient administration, RetDQoL (DAY 0)
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

RetDQoL (DAY 0) CRFs Roche FVF4168G Macular Edema NCT00473330

- 08/06/2017 - 1 Formulário, 2 Grupos de itens, 3 Elementos de dados, 1 Idioma
Grupos de itens: Patient administration, RetDQoL (DAY 0)
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Ethanol-Free Clobetasol Propionate Foam vs Vehicle Foam in Chronic Hand Dermatitis NCT01323673 - Unscheduled Visit; Concomitant Medications; Concomitant Procedures; Adverse Events; General Comments; Subject's Post-Study Questionnaire

- 30/01/2019 - 1 Formulário, 12 Grupos de itens, 60 Elementos de dados, 1 Idioma
Grupos de itens: Unscheduled Visit, Concomitant Medications, Concomitant Procedures, Adverse Events, General Comments, Subject's Post-Study Questionnaire, 1 - Skin Medicines used in past, 2 - Rate Qualities of Foam, 3 - Rate the Foam, 4 - Compare Foam to Other Types of Skin Medicines, 5 - Likely to be compliant using various types of Medicines, 6 - What do you like or not like about the Foam?
Study ID: 115054 Clinical Study ID: 115054 Study Title: Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01323673 Sponsor: GlaxoSmithKline Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Vehicle / Placebo Trade Name: clobetasol propionate Study Indication: Dermatitis, Chronic

GLOBAL HEALING CENTER - General Health Questionnaire

- 01/02/2017 - 1 Formulário, 16 Grupos de itens, 178 Elementos de dados, 1 Idioma
Grupos de itens: Overall wellbeing, Do You Have Chronic Inflammation in Your Body?, Poor Nutrition and Lifestyle, Do You Have Abnormal Blood Sugar Levels? Are You Pre-Diabetic or At Risk?, Do You Have Impaired Cellular/Mitochondrial Function?, Exposure to Toxins: Is Your Detoxification Capacity Impaired?, Is Your Home and/or Work Environment Toxic?, Impaired Immune System: What is the Quality of Your Immune System Function?, Is Your Liver Impaired by Your Emotions?, Are Your Kidney and Urinary Systems Functioning Properly?, Do You Have Parasites, Viruses, Fungi, or other Microbes Inside Your Body?, Hormonal Imbalance: Are Your Adrenal Glands Functioning Properly?, Is Your Thyroid Imbalanced?, Are Your Sex Hormones Reduced in Production or Quality?, FOR WOMEN - Is Your Body Out of Balance?, FOR MEN - Is Your Body Out of Balance?
GLOBAL HEALING CENTER - LIVE HEALTHY|General Health Questionnaire Note — This General Health Questionnaire is not intended to diagnose, treat, cure or prevent any disease. No statements herein have been evaluated by the FDA nor is any endorsement thereof implied or given. We advise use of this Questionnaire simply as a starting point for consideration of any negative health symptoms you may be experiencing and potential preventative measures or as a resource for further discussion with your healthcare provider. http://www.globalhealingcenter.com/general-health-questionnaire.html

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial